| . | Low risk N = 2641 . | Moderate risk N = 5286 . | High risk N = 3860 . | P-value . |
|---|---|---|---|---|
| Age, years | 64.2 ± 11.5 | 67.1 ± 11.3 | 67.0 ± 11.8 | <0.001 |
| BMI, kg/m2 | 28.3 ± 5.3 | 29.3 ± 5.8 | 28.6 ± 5.5 | <0.001 |
| Female sex | 644 (24.4%) | 1645 (31.1%) | 913 (23.7%) | <0.001 |
| Non-White Race/ethnicity | 1255 (47.5%) | 3199 (60.5%) | 1938 (50.2%) | <0.001 |
| Hypertension | 2099 (79.5%) | 5060 (95.7%) | 3537 (91.6%) | <0.001 |
| Hyperlipidaemia | 2108 (79.8%) | 4945 (93.5%) | 3448 (89.3%) | <0.001 |
| Diabetes Mellitus | 0 (0.0%) | 3710 (70.2%) | 1860 (48.2%) | <0.001 |
| Insulin dependent | 0 (0.0%) | 1304 (35.1%) | 692 (37.2%) | 0.139 |
| Current smoker | 608 (23.0%) | 903 (17.1%) | 1133 (29.4%) | <0.001 |
| Family history of CAD | 691 (26.2%) | 1196 (22.6%) | 858 (22.2%) | <0.001 |
| Prior PCI | 683 (25.9%) | 2703 (51.1%) | 1612 (41.8%) | <0.001 |
| Prior MI | 0 (0.0%) | 1627 (30.8%) | 1001 (25.9%) | <0.001 |
| Prior CABG | 203 (7.7%) | 991 (18.7%) | 773 (20.0%) | <0.001 |
| Peripheral artery disease | 0 (0.0%) | 678 (12.8%) | 416 (10.8%) | <0.001 |
| Prior stroke | 154 (5.8%) | 671 (12.7%) | 431 (11.2%) | <0.001 |
| Atrial fibrillation | 167 (6.3%) | 491 (9.3%) | 363 (9.4%) | <0.001 |
| Anaemia | 551 (21.4%) | 2366 (45.6%) | 1467 (39.6%) | <0.001 |
| Lung disease | 151 (5.7%) | 380 (7.2%) | 283 (7.3%) | 0.023 |
| Chronic kidney disease* | 0 (0.0%) | 1913 (38.2%) | 1030 (28.8%) | <0.001 |
| Dialysis | 0 (0.0%) | 31 (0.6%) | 29 (0.8%) | <0.001 |
| High bleeding risk# | 624 (23.6%) | 2607 (49.3%) | 1686 (43.7%) | <0.001 |
| LVEF, % | 56.1 ± 9.2 | 54.5 ± 10.8 | 53.0 ± 12.1 | <0.001 |
| PCI presentation | ||||
| Asymptomatic | 112 (4.2%) | 231 (4.4%) | 179 (4.6%) | 0.719 |
| Stable angina | 1314 (49.8%) | 2717 (51.4%) | 2084 (54.0%) | 0.002 |
| Unstable angina | 686 (26.0%) | 1589 (30.1%) | 950 (24.6%) | <0.001 |
| NSTEMI | 355 (13.4%) | 602 (11.4%) | 500 (13.0%) | 0.013 |
| STEMI | 167 (6.3%) | 118 (2.2%) | 108 (2.8%) | <0.001 |
| Discharge medication | ||||
| DAPT | 2528 (95.9%) | 5006 (94.7%) | 3605 (93.9%) | 0.002 |
| Aspirin | 2532 (96.0%) | 5012 (94.9%) | 3614 (94.1%) | 0.003 |
| P2Y12 inhibitor | 2627 (99.6%) | 5257 (99.5%) | 3807 (99.2%) | 0.039 |
| Clopidogrel | 1842 (69.9%) | 4039 (76.4%) | 2493 (64.9%) | <0.001 |
| Ticagrelor | 636 (24.1%) | 884 (16.7%) | 930 (24.2%) | <0.001 |
| Prasugrel | 156 (5.9%) | 343 (6.5%) | 401 (10.4%) | <0.001 |
| . | Low risk N = 2641 . | Moderate risk N = 5286 . | High risk N = 3860 . | P-value . |
|---|---|---|---|---|
| Age, years | 64.2 ± 11.5 | 67.1 ± 11.3 | 67.0 ± 11.8 | <0.001 |
| BMI, kg/m2 | 28.3 ± 5.3 | 29.3 ± 5.8 | 28.6 ± 5.5 | <0.001 |
| Female sex | 644 (24.4%) | 1645 (31.1%) | 913 (23.7%) | <0.001 |
| Non-White Race/ethnicity | 1255 (47.5%) | 3199 (60.5%) | 1938 (50.2%) | <0.001 |
| Hypertension | 2099 (79.5%) | 5060 (95.7%) | 3537 (91.6%) | <0.001 |
| Hyperlipidaemia | 2108 (79.8%) | 4945 (93.5%) | 3448 (89.3%) | <0.001 |
| Diabetes Mellitus | 0 (0.0%) | 3710 (70.2%) | 1860 (48.2%) | <0.001 |
| Insulin dependent | 0 (0.0%) | 1304 (35.1%) | 692 (37.2%) | 0.139 |
| Current smoker | 608 (23.0%) | 903 (17.1%) | 1133 (29.4%) | <0.001 |
| Family history of CAD | 691 (26.2%) | 1196 (22.6%) | 858 (22.2%) | <0.001 |
| Prior PCI | 683 (25.9%) | 2703 (51.1%) | 1612 (41.8%) | <0.001 |
| Prior MI | 0 (0.0%) | 1627 (30.8%) | 1001 (25.9%) | <0.001 |
| Prior CABG | 203 (7.7%) | 991 (18.7%) | 773 (20.0%) | <0.001 |
| Peripheral artery disease | 0 (0.0%) | 678 (12.8%) | 416 (10.8%) | <0.001 |
| Prior stroke | 154 (5.8%) | 671 (12.7%) | 431 (11.2%) | <0.001 |
| Atrial fibrillation | 167 (6.3%) | 491 (9.3%) | 363 (9.4%) | <0.001 |
| Anaemia | 551 (21.4%) | 2366 (45.6%) | 1467 (39.6%) | <0.001 |
| Lung disease | 151 (5.7%) | 380 (7.2%) | 283 (7.3%) | 0.023 |
| Chronic kidney disease* | 0 (0.0%) | 1913 (38.2%) | 1030 (28.8%) | <0.001 |
| Dialysis | 0 (0.0%) | 31 (0.6%) | 29 (0.8%) | <0.001 |
| High bleeding risk# | 624 (23.6%) | 2607 (49.3%) | 1686 (43.7%) | <0.001 |
| LVEF, % | 56.1 ± 9.2 | 54.5 ± 10.8 | 53.0 ± 12.1 | <0.001 |
| PCI presentation | ||||
| Asymptomatic | 112 (4.2%) | 231 (4.4%) | 179 (4.6%) | 0.719 |
| Stable angina | 1314 (49.8%) | 2717 (51.4%) | 2084 (54.0%) | 0.002 |
| Unstable angina | 686 (26.0%) | 1589 (30.1%) | 950 (24.6%) | <0.001 |
| NSTEMI | 355 (13.4%) | 602 (11.4%) | 500 (13.0%) | 0.013 |
| STEMI | 167 (6.3%) | 118 (2.2%) | 108 (2.8%) | <0.001 |
| Discharge medication | ||||
| DAPT | 2528 (95.9%) | 5006 (94.7%) | 3605 (93.9%) | 0.002 |
| Aspirin | 2532 (96.0%) | 5012 (94.9%) | 3614 (94.1%) | 0.003 |
| P2Y12 inhibitor | 2627 (99.6%) | 5257 (99.5%) | 3807 (99.2%) | 0.039 |
| Clopidogrel | 1842 (69.9%) | 4039 (76.4%) | 2493 (64.9%) | <0.001 |
| Ticagrelor | 636 (24.1%) | 884 (16.7%) | 930 (24.2%) | <0.001 |
| Prasugrel | 156 (5.9%) | 343 (6.5%) | 401 (10.4%) | <0.001 |
BMI: body mass index, CABG: coronary artery bypass graft, CAD: coronary artery disease, DAPT: dual antiplatelet therapy, LVEF: left ventricle ejection fraction, MI: myocardial infarction, NSTEMI: non-ST segment elevation myocardial infarction, PCI: percutaneous coronary intervention, STEMI: ST segment elevation myocardial infarction
estimated glomerular filtration rate <60 mL/min.
meeting at least 1 major or 2 minor HBR criteria based on the ARC definition.
| . | Low risk N = 2641 . | Moderate risk N = 5286 . | High risk N = 3860 . | P-value . |
|---|---|---|---|---|
| Age, years | 64.2 ± 11.5 | 67.1 ± 11.3 | 67.0 ± 11.8 | <0.001 |
| BMI, kg/m2 | 28.3 ± 5.3 | 29.3 ± 5.8 | 28.6 ± 5.5 | <0.001 |
| Female sex | 644 (24.4%) | 1645 (31.1%) | 913 (23.7%) | <0.001 |
| Non-White Race/ethnicity | 1255 (47.5%) | 3199 (60.5%) | 1938 (50.2%) | <0.001 |
| Hypertension | 2099 (79.5%) | 5060 (95.7%) | 3537 (91.6%) | <0.001 |
| Hyperlipidaemia | 2108 (79.8%) | 4945 (93.5%) | 3448 (89.3%) | <0.001 |
| Diabetes Mellitus | 0 (0.0%) | 3710 (70.2%) | 1860 (48.2%) | <0.001 |
| Insulin dependent | 0 (0.0%) | 1304 (35.1%) | 692 (37.2%) | 0.139 |
| Current smoker | 608 (23.0%) | 903 (17.1%) | 1133 (29.4%) | <0.001 |
| Family history of CAD | 691 (26.2%) | 1196 (22.6%) | 858 (22.2%) | <0.001 |
| Prior PCI | 683 (25.9%) | 2703 (51.1%) | 1612 (41.8%) | <0.001 |
| Prior MI | 0 (0.0%) | 1627 (30.8%) | 1001 (25.9%) | <0.001 |
| Prior CABG | 203 (7.7%) | 991 (18.7%) | 773 (20.0%) | <0.001 |
| Peripheral artery disease | 0 (0.0%) | 678 (12.8%) | 416 (10.8%) | <0.001 |
| Prior stroke | 154 (5.8%) | 671 (12.7%) | 431 (11.2%) | <0.001 |
| Atrial fibrillation | 167 (6.3%) | 491 (9.3%) | 363 (9.4%) | <0.001 |
| Anaemia | 551 (21.4%) | 2366 (45.6%) | 1467 (39.6%) | <0.001 |
| Lung disease | 151 (5.7%) | 380 (7.2%) | 283 (7.3%) | 0.023 |
| Chronic kidney disease* | 0 (0.0%) | 1913 (38.2%) | 1030 (28.8%) | <0.001 |
| Dialysis | 0 (0.0%) | 31 (0.6%) | 29 (0.8%) | <0.001 |
| High bleeding risk# | 624 (23.6%) | 2607 (49.3%) | 1686 (43.7%) | <0.001 |
| LVEF, % | 56.1 ± 9.2 | 54.5 ± 10.8 | 53.0 ± 12.1 | <0.001 |
| PCI presentation | ||||
| Asymptomatic | 112 (4.2%) | 231 (4.4%) | 179 (4.6%) | 0.719 |
| Stable angina | 1314 (49.8%) | 2717 (51.4%) | 2084 (54.0%) | 0.002 |
| Unstable angina | 686 (26.0%) | 1589 (30.1%) | 950 (24.6%) | <0.001 |
| NSTEMI | 355 (13.4%) | 602 (11.4%) | 500 (13.0%) | 0.013 |
| STEMI | 167 (6.3%) | 118 (2.2%) | 108 (2.8%) | <0.001 |
| Discharge medication | ||||
| DAPT | 2528 (95.9%) | 5006 (94.7%) | 3605 (93.9%) | 0.002 |
| Aspirin | 2532 (96.0%) | 5012 (94.9%) | 3614 (94.1%) | 0.003 |
| P2Y12 inhibitor | 2627 (99.6%) | 5257 (99.5%) | 3807 (99.2%) | 0.039 |
| Clopidogrel | 1842 (69.9%) | 4039 (76.4%) | 2493 (64.9%) | <0.001 |
| Ticagrelor | 636 (24.1%) | 884 (16.7%) | 930 (24.2%) | <0.001 |
| Prasugrel | 156 (5.9%) | 343 (6.5%) | 401 (10.4%) | <0.001 |
| . | Low risk N = 2641 . | Moderate risk N = 5286 . | High risk N = 3860 . | P-value . |
|---|---|---|---|---|
| Age, years | 64.2 ± 11.5 | 67.1 ± 11.3 | 67.0 ± 11.8 | <0.001 |
| BMI, kg/m2 | 28.3 ± 5.3 | 29.3 ± 5.8 | 28.6 ± 5.5 | <0.001 |
| Female sex | 644 (24.4%) | 1645 (31.1%) | 913 (23.7%) | <0.001 |
| Non-White Race/ethnicity | 1255 (47.5%) | 3199 (60.5%) | 1938 (50.2%) | <0.001 |
| Hypertension | 2099 (79.5%) | 5060 (95.7%) | 3537 (91.6%) | <0.001 |
| Hyperlipidaemia | 2108 (79.8%) | 4945 (93.5%) | 3448 (89.3%) | <0.001 |
| Diabetes Mellitus | 0 (0.0%) | 3710 (70.2%) | 1860 (48.2%) | <0.001 |
| Insulin dependent | 0 (0.0%) | 1304 (35.1%) | 692 (37.2%) | 0.139 |
| Current smoker | 608 (23.0%) | 903 (17.1%) | 1133 (29.4%) | <0.001 |
| Family history of CAD | 691 (26.2%) | 1196 (22.6%) | 858 (22.2%) | <0.001 |
| Prior PCI | 683 (25.9%) | 2703 (51.1%) | 1612 (41.8%) | <0.001 |
| Prior MI | 0 (0.0%) | 1627 (30.8%) | 1001 (25.9%) | <0.001 |
| Prior CABG | 203 (7.7%) | 991 (18.7%) | 773 (20.0%) | <0.001 |
| Peripheral artery disease | 0 (0.0%) | 678 (12.8%) | 416 (10.8%) | <0.001 |
| Prior stroke | 154 (5.8%) | 671 (12.7%) | 431 (11.2%) | <0.001 |
| Atrial fibrillation | 167 (6.3%) | 491 (9.3%) | 363 (9.4%) | <0.001 |
| Anaemia | 551 (21.4%) | 2366 (45.6%) | 1467 (39.6%) | <0.001 |
| Lung disease | 151 (5.7%) | 380 (7.2%) | 283 (7.3%) | 0.023 |
| Chronic kidney disease* | 0 (0.0%) | 1913 (38.2%) | 1030 (28.8%) | <0.001 |
| Dialysis | 0 (0.0%) | 31 (0.6%) | 29 (0.8%) | <0.001 |
| High bleeding risk# | 624 (23.6%) | 2607 (49.3%) | 1686 (43.7%) | <0.001 |
| LVEF, % | 56.1 ± 9.2 | 54.5 ± 10.8 | 53.0 ± 12.1 | <0.001 |
| PCI presentation | ||||
| Asymptomatic | 112 (4.2%) | 231 (4.4%) | 179 (4.6%) | 0.719 |
| Stable angina | 1314 (49.8%) | 2717 (51.4%) | 2084 (54.0%) | 0.002 |
| Unstable angina | 686 (26.0%) | 1589 (30.1%) | 950 (24.6%) | <0.001 |
| NSTEMI | 355 (13.4%) | 602 (11.4%) | 500 (13.0%) | 0.013 |
| STEMI | 167 (6.3%) | 118 (2.2%) | 108 (2.8%) | <0.001 |
| Discharge medication | ||||
| DAPT | 2528 (95.9%) | 5006 (94.7%) | 3605 (93.9%) | 0.002 |
| Aspirin | 2532 (96.0%) | 5012 (94.9%) | 3614 (94.1%) | 0.003 |
| P2Y12 inhibitor | 2627 (99.6%) | 5257 (99.5%) | 3807 (99.2%) | 0.039 |
| Clopidogrel | 1842 (69.9%) | 4039 (76.4%) | 2493 (64.9%) | <0.001 |
| Ticagrelor | 636 (24.1%) | 884 (16.7%) | 930 (24.2%) | <0.001 |
| Prasugrel | 156 (5.9%) | 343 (6.5%) | 401 (10.4%) | <0.001 |
BMI: body mass index, CABG: coronary artery bypass graft, CAD: coronary artery disease, DAPT: dual antiplatelet therapy, LVEF: left ventricle ejection fraction, MI: myocardial infarction, NSTEMI: non-ST segment elevation myocardial infarction, PCI: percutaneous coronary intervention, STEMI: ST segment elevation myocardial infarction
estimated glomerular filtration rate <60 mL/min.
meeting at least 1 major or 2 minor HBR criteria based on the ARC definition.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
